Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Oct 27, 2022 11:00am
173 Views
Post# 35053095

RE:Shake shake the trees!

RE:Shake shake the trees!I added some more last week. $1.74 level.
iMHO.
the actual buy- in price will be somewhat irrelevant, should Onc get into the analyst range of $6ps to $15ps.
that said. Those predictions do not include anything at all fo4 the upcoming Goblet Panc results we are about to get in 2 weeks.
assuming they additional patients see the same 48% tumour reduction alongside the co therapy with Roche ( tecentriq), then Onc Pelareorep becomes a blockbuster drug.
SP?
pick a number.
So, while we whittle away, low volume +/- a few cents/ day.
The presentations 15th of November, could create a whole new world.
so far all the build up looks positive. They would not spend the time or $$ to come out with bad news.

<< Previous
Bullboard Posts
Next >>